Revenue

12 Months Ended

Dec. 31, 2021

Revenue From Contract With Customer [Abstract]

Revenue

15. Revenue

The Company has determined that the payments made to the customer for reimbursement of clinical trial materials and customer’s costs incurred to execute specific clinical trial protocols related to the Company’s OCS products do not provide the Company with a distinct good or service transferred by the customer, and therefore such payments are recorded as a reduction of revenue from the customer in the Company’s consolidated statements of operations. Reductions of revenue related to such payments made to customers for reimbursements are recognized when the Company recognizes the revenue for the sale of its OCS disposable sets.

The reconciliation of gross revenue to net revenue for these certain payments is shown below (in thousands):

	Year Ended December 31,
	2021		2020
Gross revenue from sales to customers	$	31,385	$	28,356
Less: Clinical trial payments reducing revenue		1,123		2,717
Total net revenue	$	30,262	$	25,639

The Company determined that payments made to customers to obtain information related to post-approval studies or existing standard-of-care protocols (i.e., unrelated to the Company’s OCS products) meet the criteria to be classified as a cost because the Company receives a distinct good or service transferred by the customer separate from the customer’s purchase of the Company’s OCS products and the consideration paid to the customer represents the fair value of the distinct good or service received. As a result, such payments made to the customers are recorded as operating expenses. The Company recorded payments made to customers related to post-approval studies and for documentation related to existing standard-of-care protocols of $2.1 million and $1.6 million for the years ended December 31, 2021 and 2020, respectively, as operating expenses.

Disaggregated Revenue

The Company disaggregates revenue from contracts with customers by product type and geographical area as it believes this presentation best depicts how the nature, amount, timing and uncertainty of the Company’s revenue and cash flows are affected by economic factors, as shown below (in thousands):

	Year Ended December 31,
	2021		2020
Net revenue by OCS product:
OCS Lung net revenue	$	10,665	$	6,194
OCS Heart net revenue		17,683		14,196
OCS Liver net revenue		1,914		5,249
Total net revenue	$	30,262	$	25,639

	Year Ended December 31,
	2021		2020
Net revenue by country (1):
United States	$	21,861	$	19,239
All other countries		8,401		6,400
Total net revenue	$	30,262	$	25,639

(1) Net revenue by country is categorized based on the location of the end customer.